Lilly declares third-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding...
Monday, June 23, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Eli Lilly and Company (NYSE: LLY) has announced a dividend of $1.50 per share for the third quarter of 2025, payable on September 10, 2025. Shareholders of record on August 15, 2025, will be eligible for this payment. The announcement reflects Lilly's confidence in its financial health, although it also includes caution about potential risks in pharmaceutical research and development. The company emphasizes the possibility of variance in actual results compared to expectations due to various uncertainties.
Price reaction · baseline $762.73 (2025-06-20 close) · clean, no other LLY news in the window
day 0 close · peak
+1%
Market Sentiment Analysis
POSITIVE FACTORS
Lilly has declared a dividend of $1.50 per share, indicating strong financial performance.
The dividend payment reaffirms shareholder value and commitment to returning profits.
The upcoming payment date demonstrates stability in the company's operations.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
2%
average across 15 past catalysts
Lead asset
Dulaglutide
Phase 3 · Type 2 Diabetes Mellitus
Full Press Release Details
INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock.
The dividend is payable on September 10, 2025 , to shareholders of record at the close of business on August 15, 2025 .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company's business and actual results may differ materially due to various factors. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.